Risk factors and event rates in patients with atherothrombotic disease in Germany: Results of the REACH registry;Ambulante patienten mit atherothrombotischen Erkrankungen: Ergebnisse des REACH-registers

Deutsches Arzteblatt

Volumn 105, Issue 45, 2008, Pages 769-775

  Zeymer, Uwe ^a   Parhofer, Klaus G ^c   Senges, Jochen ^b   Röther, Joachim ^d  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Arterial occlusion; Cardiovascular risk factors; Coronary heart disease; Outpatient care; Stroke

Indexed keywords

ARTICLE; ATHEROTHROMBOTIC DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; FOLLOW UP; GERMANY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; OBESITY; PRACTICE GUIDELINE; STROKE; THROMBOSIS;

EID: 56749119943     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2008.0769     Document Type: Article

References (25)

1. Bhatt DL, Roe MT, Peterson ED et al.: Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Jama 2004; 292: 2096-104.
2. Zeymer U, Gitt AK, Junger C et al.: Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 2006; 27: 2661-6.
3. Eagle KA, Kline-Rogers E, Goodman SG et al.: Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117: 73-81.
4. Hasdai D, Behar S, Wallentin L et al.: A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190-201.
5. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
6. Yusuf S, Hawken S, Ounpuu S et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
7. Conroy RM, Pyorala K, Fitzgerald AP et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
8. Ohman EM, Bhatt DL, Steg PG et al.: The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006; 151: 786 e1-10.
9. Bhatt DL, Steg PG, Ohman EM et al.: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.
10. De Backer G, Ambrosioni E, Borch-Johnsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
11. Diener HC, Allenberg JR, Bode C et al.: Leitlinie Primär- und Sekundärprävention der zerebralen Ischämie. Stuttgart: Thieme Verlag 2005.
12. Dietz R, Rauch B: Leitlinie zur Behandlung der chronischen koronaren Herzkrankheit der Deutschen Gesellschaft für Kardiologie. Z Kardiol 2003; 92: 501-21.
13. Gohlke H, Schuler G: Prävention kardiovaskulärer Erkrankungen. Z Kardiol 2004; 93; Supplement 3.
14. Norgren L, Hiatt WR, Dormandy JA et al.: Intersociety consensus for the management of peripheral arterial disease (TASC 2). Eur J Vasc Endovasc Surg 2007; 33: Supplement 1: 1-68.
15. Williams MA, Fleg JL, Ades PA et al.: Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥ 75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on exercise, cardiac rehabilitation, and prevention. Circulation 2002; 105: 1735-43.
16. CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
17. Diehm C, Schuster A, Allenberg JR et al.: High prevalence of peripheral arterial disease and co-morbidity in 6 880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172: 95-105.
18. Böhler S, Scharnagel H, Freisinger F et al.: Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 207; 190: 397-407.
19. Pittrow D, Stalla GK, Zeiher AM et al.: Prävalenz, medikamentöse Behandlung und Einstellung des Diabetes mellitus in der Hausarztpraxis. Med Klin (Munich) 2006; 101: 135-644.
20. Berthold HK, Gouni-Berthold I, Bestehorn K et al.: Kardiale Risikofaktoren bei Typ-2-Diabetikern in Deutschland - ein Versorgungsparadox. Dtsch Ärztebl 2007; 104(13): A 861-7.
21. Abholz HH: Versorgung von Typ-2-Diabetikern: eine Arbeit, zwei Interpretationen. Dtsch Ärztebl 2007; 104(13): A 859-60.
22. NICE clinical guideline 48. Myocardial infarction: secondary prevention. www.nice.org.uk/CG048
23. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB: Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867-72.
24. Yusuf S, Hawken S, Ounpuu S et al.: Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-9.
25. Steg PG, Bhatt DL, Wilson PWF et al.: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-206.